Detects porcine IL-4 in Western blots. In Western blots, 100% cross-reactivity with recombinant mouse IL-4 is observed, 15% with recombinant rat IL-4 is observed, and no cross-reactivity with recombinant bovine IL-4, recombinant canine IL-4, recombinant cotton rat IL-4, recombinant equine IL-4, recombinant feline IL-4, recombinant human IL-4, or recombinant human IL-13 is observed.
Monoclonal Mouse IgG1 Clone # 286120
Protein A or G purified from hybridoma culture supernatant
E. coli-derived recombinant porcine IL-4 His25-Cys133 Accession # Q04745
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Measured by its ability to neutralize IL‑4-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.3-1.2 µg/mL in the presence of 30 ng/mL Recombinant Porcine IL‑4.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Cell Proliferation Induced by IL‑4 and Neutralization by Porcine IL‑4 Antibody. Recombinant Porcine IL‑4 (Catalog # 654-P4) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Porcine IL‑4 (30 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Porcine IL‑4 Monoclonal Antibody (Catalog # MAB6542). The ND50 is typically 0.3-1.2 µg/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13‑18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1 ‑ 3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four alpha -helix structure (4). Porcine IL-4 is synthesized with a 24 amino acid (aa) signal sequence. Mature porcine IL-4 shares 78%, 59%, 41%, and 41% aa sequence identity with bovine, human, mouse, and rat IL-4, respectively. Human IL-4 is active on porcine vascular endothelial cells (5). IL-4 exerts its effects through two receptor complexes (6, 7). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 R alpha and the common gamma chain (a shared subunit of the receptors for IL‑2, ‑7, ‑9, ‑15, and -21). The type II receptor on nonhematopoietic cells consists of IL-4 R alpha and IL-13 R alpha 1. The type II receptor also transduces IL-13 mediated signals. IL‑4 is primarily expressed by Th2-biased CD4+ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgE in B cells, acquisition of the Th2 phenotype by naïve CD4+ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (8, 11). IL-4 plays a dominant role in the development of allergic inflammation and asthma (10, 12).
Benczik, M. and S.L. Gaffen (2004) Immunol. Invest. 33:109.
Chomarat, P. and J. Banchereau (1998) Int. Rev. Immunol. 17:1.
Bailey, M. et al. (1993) Biochim. Biophys. Acta 1171:328.
Redfield, C. et al. (1991) Biochemistry 30:11029.
Stocker, C.J. et al. (2000) J. Immunol. 164:3309.
Mueller, T.D. et al. (2002) Biochim. Biophys. Acta 1592:237.
Nelms, K. et al. (1999) Annu. Rev. Immunol. 17:701.
Paludan, S.R. (1998) Scand. J. Immunol. 48:459.
Corthay, A. (2006) Scand. J. Immunol. 64:93.
Ryan, J.J. et al. (2007) Crit. Rev. Immunol. 27:15.
Grone, A. (2002) Vet. Immunol. Immunopathol. 88:1.
Rosenberg, H.F. et al. (2007) J. Allergy Clin. Immunol. 119:1303.